The Dyspnoea, Obstruction, Smoking, Exacerbation (DOSE) Index is Predictive of Mortality in COPD

Overview

Journal Prim Care Respir J

Specialties Public Health
Pulmonary Medicine

Date 2012 Jul 13

PMID 22786813

Citations 43

Authors

Josefin Sundh

Christer Janson

Karin Lisspers

Bjorn Stallberg

Scott Montgomery

Affiliations

Soon will be listed here.

Abstract

Background: The Dyspnoea, Obstruction, Smoking, Exacerbation (DOSE) index was designed to assess disease severity and for the clinical management of chronic obstructive pulmonary disease (COPD), but has not been evaluated as a prognostic instrument for mortality in a population including primary care patients.

Aims: The aim of this study was to investigate the associations of the DOSE index with mortality in primary and secondary care COPD patients.

Methods: Information was collected from 1,111 COPD patients aged 34-75 years randomly selected from 70 Swedish primary and secondary care centres. Data were obtained using patient questionnaires and record review and the Swedish Board of Health and Welfare provided mortality data. The study population included 562 patients with data on all DOSE index components. The DOSE index was calculated using the MRC dyspnoea scale, forced expiratory volume in 1 second (FEV₁) as percentage of predicted (FEV₁%pred), smoking status, and exacerbation rate. The exacerbation rate over 6 months prior to record review was used to estimate the annual rate. Cox regression analyses estimated survival with adjustment for age, sex, and heart disease.

Results: Over 5 years, 116 patients (20.6%) died. Mortality was higher in patients with DOSE index ≥4 (42.4%) than for lower scores (11.0%) (p<0.0001). Compared with a DOSE index score of 0-3, the hazard ratio for mortality was 3.48 (95% CI 2.32 to 5.22) for a score of 4-5, and was 8.00 (95% CI 4.67 to 13.7) for a score of 6-7.

Conclusions: The DOSE index is associated with mortality in COPD patients in primary and secondary care and can be used to assess prognosis in addition to other clinically relevant issues.

Citing Articles

Development and validation of a novel AI-derived index for predicting COPD medical costs in clinical practice.

Liu G, Li C, Yang C, Liu S Comput Struct Biotechnol J. 2025; 27:541-547.

PMID: 39981294 PMC: 11840938. DOI: 10.1016/j.csbj.2025.01.015.

Validation of new predictors of mortality and BODE index variants in patients with COPD at moderate altitude.

Robles-Hernandez R, Centeno-Saenz G, Ramirez-Venegas A, Thirion-Romero I, Hernandez-Zenteno R, Guinto-Ramirez S ERJ Open Res. 2025; 11(1).

PMID: 39872381 PMC: 11770809. DOI: 10.1183/23120541.00333-2024.

Study protocol for evaluating the efficacy of early pulmonary rehabilitation combined with an internet-based patient management model in patients with COPD: a practical, multicentre, randomised controlled study from China.

Ye W, Danye L, Jingjing C, Siyu Z, Jiaxi W, Siyuan W ERJ Open Res. 2024; 10(5).

PMID: 39469268 PMC: 11513996. DOI: 10.1183/23120541.00995-2023.

Clinical efficacy and safety of the self-developed Zangsiwei Qingfei Mixture combined with conventional treatment in patients with acute exacerbation of chronic obstructive pulmonary disease.

Yi Q, Li F, Lei S, Peng F, Zhang Q, Wu Y Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2024; 49(6):921-931.

PMID: 39311788 PMC: 11420969. DOI: 10.11817/j.issn.1672-7347.2024.230546.

Mortality prevention as the centre of COPD management.

Papaioannou A, Hillas G, Loukides S, Vassilakopoulos T ERJ Open Res. 2024; 10(3).

PMID: 38887682 PMC: 11181087. DOI: 10.1183/23120541.00850-2023.

References

Groenewegen K, Schols A, Wouters E . Mortality and mortality-related factors after hospitalization for acute exacerbation of COPD. Chest. 2003; 124(2):459-67. DOI: 10.1378/chest.124.2.459. View

Rabe K, Beghe B, Luppi F, Fabbri L . Update in chronic obstructive pulmonary disease 2006. Am J Respir Crit Care Med. 2007; 175(12):1222-32. DOI: 10.1164/rccm.200704-586UP. View

Siafakas N, Vermeire P, Pride N, Paoletti P, Gibson J, Howard P . Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. Eur Respir J. 1995; 8(8):1398-420. DOI: 10.1183/09031936.95.08081398. View

Anthonisen N, Skeans M, Wise R, Manfreda J, Kanner R, Connett J . The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med. 2005; 142(4):233-9. DOI: 10.7326/0003-4819-142-4-200502150-00005. View

Nishimura K, Izumi T, Tsukino M, Oga T . Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest. 2002; 121(5):1434-40. DOI: 10.1378/chest.121.5.1434. View

Gudmundsson G, Gislason T, Lindberg E, Hallin R, Ulrik C, Brondum E . Mortality in COPD patients discharged from hospital: the role of treatment and co-morbidity. Respir Res. 2006; 7:109. PMC: 1560381. DOI: 10.1186/1465-9921-7-109. View

Drummond M, Wise R, John M, Zvarich M, McGarvey L . Accuracy of death certificates in COPD: analysis from the TORCH trial. COPD. 2010; 7(3):179-85. PMC: 4802970. DOI: 10.3109/15412555.2010.481695. View

Jones R, Donaldson G, Chavannes N, Kida K, Dickson-Spillmann M, Harding S . Derivation and validation of a composite index of severity in chronic obstructive pulmonary disease: the DOSE Index. Am J Respir Crit Care Med. 2009; 180(12):1189-95. DOI: 10.1164/rccm.200902-0271OC. View

Murray C, Lopez A . Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet. 1997; 349(9064):1498-504. DOI: 10.1016/S0140-6736(96)07492-2. View

10.

Hurd S . The impact of COPD on lung health worldwide: epidemiology and incidence. Chest. 2000; 117(2 Suppl):1S-4S. DOI: 10.1378/chest.117.2_suppl.1s. View

11.

Tashkin D, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S . A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008; 359(15):1543-54. DOI: 10.1056/NEJMoa0805800. View

12.

Kanner R, Anthonisen N, Connett J . Lower respiratory illnesses promote FEV(1) decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: results from the lung health study. Am J Respir Crit Care Med. 2001; 164(3):358-64. DOI: 10.1164/ajrccm.164.3.2010017. View

13.

Jensen H, Godtfredsen N, Lange P, Vestbo J . Potential misclassification of causes of death from COPD. Eur Respir J. 2006; 28(4):781-5. DOI: 10.1183/09031936.06.00152205. View

14.

Mahler D, Wells C . Evaluation of clinical methods for rating dyspnea. Chest. 1988; 93(3):580-6. DOI: 10.1378/chest.93.3.580. View

15.

Hersh C, DeMeo D, Al-Ansari E, Carey V, Reilly J, Ginns L . Predictors of survival in severe, early onset COPD. Chest. 2004; 126(5):1443-51. DOI: 10.1378/chest.126.5.1443. View

16.

Hansell A, Walk J, Soriano J . What do chronic obstructive pulmonary disease patients die from? A multiple cause coding analysis. Eur Respir J. 2003; 22(5):809-14. DOI: 10.1183/09031936.03.00031403. View

17.

Oga T, Tsukino M, Hajiro T, Ikeda A, Nishimura K . Predictive properties of different multidimensional staging systems in patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2011; 6:521-6. PMC: 3206768. DOI: 10.2147/COPD.S24420. View

18.

Cote C, Pinto-Plata V, Marin J, Nekach H, Dordelly L, Celli B . The modified BODE index: validation with mortality in COPD. Eur Respir J. 2008; 32(5):1269-74. DOI: 10.1183/09031936.00138507. View

19.

Calverley P, Anderson J, Celli B, Ferguson G, Jenkins C, Jones P . Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007; 356(8):775-89. DOI: 10.1056/NEJMoa063070. View

20.

Fletcher C, ELMES P, FAIRBAIRN A, Wood C . The significance of respiratory symptoms and the diagnosis of chronic bronchitis in a working population. Br Med J. 1959; 2(5147):257-66. PMC: 1990153. DOI: 10.1136/bmj.2.5147.257. View